Wockhardt Ltd
WOCKPHARMA NSE
Wockhardt Ltd
HealthcareNSE: WOCKPHARMA BSE: 532300 Pharmaceuticals
Key Fundamentals
SmallcapPharmaceuticalsHealthcareMarket Cap
₹30,484 Cr
Volatility
Moderate
P/E Ratio
146.99
EBITDA
₹567 Cr
Debt to Equity
0.57
Book Value
₹304.03
52W High
₹2,422.3
52W Low
₹1,086.7
Technical Indicators
Key Insights
Weaknesses
5- Stock is trading at 6.03 times its book value
- The company has delivered a poor sales growth of 4.49% over past five years.
- Company has a low return on equity of -1.43% over last 3 years.
- Promoter holding has decreased over last 3 years: -10.2%
- Working capital days have increased from -27.3 days to 89.3 days
Growth Rate
Revenue Growth
9.73% ↘
Net Income Growth
-485.96% ↘
Cash Flow Change
-110.05% ↘
ROE
-90.54% ↘
ROCE
-264.98% ↘
EBITDA Margin (Avg.)
9.93% ↘
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 678 | 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 |
| Expenses | 675 | 628 | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 |
| Operating Profit | 3 | 16 | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 |
| OPM % | 0% | 2% | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% | 23% | 20% | 23% |
| Other Income | -64 | 0 | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 | 21 | 15 | 67 |
| Interest | 76 | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 |
| Depreciation | 56 | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 |
| PBT | -193 | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 | 67 | 189 |
| Tax % | 23% | 15% | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% | 10% | 9% | 13% |
| Net Profit | -237 | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 | 82 | 61 | 164 |
| EPS in Rs | -14.44 | -9.3 | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 | 4.8 | 3.63 | 10.22 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 |
| Expenses | 3,772 | 3,959 | 4,002 | 3,935 | 3,604 | 2,725 | 2,771 | 2,932 | 2,550 | 2,707 | 2,619 | 2,721 |
| Operating Profit | 709 | 494 | 13 | 2 | -38 | 119 | -63 | 298 | 101 | 91 | 393 | 652 |
| OPM % | 16% | 11% | 0% | 0% | -1% | 4% | -2% | 9% | 4% | 3% | 13% | 19% |
| Other Income | 67 | 66 | 114 | -238 | 116 | 133 | 975 | -163 | -172 | 17 | 62 | 26 |
| Interest | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 213 |
| Depreciation | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 217 | 227 |
| PBT | 575 | 289 | -247 | -641 | -351 | -247 | 417 | -411 | -624 | -420 | -16 | 238 |
| Tax % | 28% | 13% | -9% | 4% | -38% | -82% | -65% | -32% | 0% | 12% | 256% | 16% |
| Net Profit | 413 | 252 | -226 | -667 | -217 | -43 | 689 | -279 | -621 | -472 | -57 | 199 |
| EPS in Rs | 28.3 | 17.45 | -13.62 | -42.3 | -13.52 | -4.81 | 47.64 | -16.94 | -38.8 | -30.18 | -2.89 | 13.11 |
| Div. Payout % | 54% | 0% | -56% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 | 81 | 81 |
| Reserves | 3,362 | 3,720 | 3,281 | 2,797 | 2,619 | 2,616 | 3,321 | 3,777 | 3,282 | 3,282 | 4,272 | 4,859 |
| Borrowings | 2,309 | 2,677 | 4,160 | 3,748 | 3,375 | 3,582 | 2,673 | 2,198 | 2,184 | 2,356 | 2,021 | 2,233 |
| Other Liabilities | 1,213 | 1,622 | 1,486 | 1,528 | 1,764 | 1,894 | 1,695 | 2,168 | 2,113 | 1,899 | 1,726 | 1,442 |
| Total Liabilities | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,744 | 8,215 | 7,651 | 7,614 | 8,100 | 8,615 |
| Fixed Assets | 2,123 | 2,809 | 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 2,881 | 2,736 | 4,499 |
| CWIP | 1,007 | 1,036 | 1,244 | 1,433 | 1,445 | 1,585 | 1,379 | 1,342 | 1,539 | 1,722 | 2,033 | 671 |
| Investments | 341 | 0 | 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 | 422 | 412 |
| Other Assets | 3,468 | 4,228 | 4,403 | 3,593 | 3,309 | 3,060 | 3,022 | 3,411 | 3,070 | 3,011 | 2,909 | 3,033 |
| Total Assets | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,744 | 8,215 | 7,651 | 7,614 | 8,100 | 8,615 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 355 | -42 | -269 | 68 | 183 | 649 | -287 | 413 | 153 | 219 | -22 | 390 |
| Investing | -222 | -105 | -684 | 635 | 93 | -147 | 1,471 | -204 | -118 | -138 | -780 | -241 |
| Financing | -76 | 193 | 1,254 | -769 | -776 | -680 | -1,171 | -71 | -315 | 334 | 409 | -54 |
| Net Cash Flow | 57 | 46 | 301 | -66 | -500 | -178 | 13 | 138 | -280 | 415 | -393 | 95 |
| Free Cash Flow | -76 | -105 | -678 | -238 | 127 | 486 | -452 | 202 | 23 | 69 | -377 | 76 |
| CFO/OP | 73 | -8 | -1,887 | 4,697 | -583 | 560 | 270 | 171 | 162 | 274 | -13 | 63 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 91 | 94 | 89 | 130 | 159 | 124 | 104 | 110 | 81 | 80 | 64 |
| Inventory Days | 250 | 249 | 243 | 174 | 183 | 209 | 257 | 222 | 216 | 201 | 234 | 286 |
| Days Payable | 136 | 144 | 117 | 122 | 187 | 272 | 186 | 265 | 285 | 240 | 191 | 182 |
| Cash Conversion Cycle | 175 | 196 | 220 | 141 | 126 | 97 | 195 | 60 | 41 | 41 | 123 | 168 |
| Working Capital Days | 14 | 52 | 36 | -56 | -51 | -171 | -133 | -116 | -186 | -148 | -23 | 89 |
| ROCE % | 10% | 7% | -1% | -1% | -1% | -1% | -3% | 1% | 0% | -1% | 4% | 8% |
Documents
1
Board Meeting Outcome for Outcome Of The Board Meeting Held On 4Th May, 2026
4 May - Board approved FY26 audited results; standalone profit Rs317 crore, consolidated profit Rs199 crore, and proposed fund raise. 4 May - Board approved FY26 audited results; standalone profit Rs317 crore, consolidated profit Rs199 crore, and proposed fund raise.
3
Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 May - Wockhardt reported FY26 PBT of Rs.238 crore, revenue of Rs.3,373 crore, and Q4 FY26 PBT of Rs.189 crore. 4 May - Wockhardt reported FY26 PBT of Rs.238 crore, revenue of Rs.3,373 crore, and Q4 FY26 PBT of Rs.189 crore.
4
Announcement under Regulation 30 (LODR)-Change in Management
4 May - Wockhardt designated Annapurna Das, Om Narayan and Sunil Soni as SMPs on 4 May 2026. 4 May - Wockhardt designated Annapurna Das, Om Narayan and Sunil Soni as SMPs on 4 May 2026.
5
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
4 May - Wockhardt reports QIP proceeds monitoring for quarter ended March 31, 2026; no deviation, utilization extended to FY2028. 4 May - Wockhardt reports QIP proceeds monitoring for quarter ended March 31, 2026; no deviation, utilization extended to FY2028.
Frequently Asked Questions about Wockhardt Ltd
What does Wockhardt Ltd do?
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
Where is Wockhardt Ltd (WOCKPHARMA) listed?
Wockhardt Ltd is listed on the Indian stock exchanges. It is listed on NSE: WOCKPHARMA and BSE: 532300. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Wockhardt Ltd belong to?
Wockhardt Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Wockhardt Ltd?
Wockhardt Ltd has a market capitalisation of approximately ₹30483.53 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Wockhardt Ltd?
The Price-to-Earnings (PE) ratio of Wockhardt Ltd is 146.99. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Wockhardt Ltd?
Over the past 52 weeks, Wockhardt Ltd has traded between a low of ₹1,086.7 and a high of ₹2,422.3. This range helps investors understand the stock's price volatility and recent trading levels.
How can I research Wockhardt Ltd on Tapetide?
On Tapetide, you can view Wockhardt Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
Website wockhardt.com
CEO Dr. Habil Fakhruddin Khorakiwala
Employees 2,296
Listed 2000-02-23
Face Value ₹ 5
Issued Size 16,24,92,169